Background
This report describes the use of combined laser photocoagulation and intravitreal bevacizumab administration for aggressive
zone I retinopathy of prematurity (ROP).
Methods
A male patient, born at 25 weeks gestation with a birth weight of 884 g, received indirect laser photocoagulation and a 0.75 mg
intravitreal bevacizumab injection to each eye for aggressive stage 3 zone I ROP. Structural outcomes were evaluated 3 months
after treatment.
Results
At 3-month follow-up, treatment had resulted in ROP regression, prompt resolution of plus signs and neovascular proliferation
in both eyes, and no signs of systemic or ocular adverse events.
Conclusions
The combination of indirect laser photocoagulation and intravitreal bevacizumab injection was well tolerated and induced prompt
regression of aggressive zone I ROP.
Keywords Retinopathy of prematurity - Indirect laser photocoagulation - Intravitreal bevacizumab injection